{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:25:02Z","timestamp":1790447102581,"version":"4.1.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Abraxane\n                      <jats:sup>\u00ae<\/jats:sup>\n                      intravenous infusion (albumin-bound paclitaxel nanoparticles; Abraxane\n                      <jats:sup>\u00ae<\/jats:sup>\n                      or paclitaxel nanoparticles) is a lyophilized cake formulation containing paclitaxel and human serum albumin in nanoparticulate form. Before use, it must be uniformly dispersed in saline. However, this reconstitution process often leads to foaming, necessitating careful handling and prolonging preparation time. This study aimed to investigate shaking conditions for rapid, uniform paclitaxel nanoparticle dispersion while minimizing foam formation. Additionally, we evaluated whether shaking affects nanoparticle size.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After adding 20\u2005mL of saline to a vial containing 100\u2005mg of lyophilized cake, the vial was placed either vertically or horizontally on a shaker. Two shaking types were examined: linear reciprocal and orbital shaking. We varied shaking intensity and recorded the dispersion time and foam formation. Particle size was analyzed under the following three conditions: (1) control, (2) minimal dispersion time without foaming, and (3) the condition causing the most severe foaming.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When the vial was placed horizontally and subjected to orbital shaking at 100\u2005rpm, uniform dispersion was achieved within 6.25\u2005min without foaming. This was approximately one-third the time required under control conditions. Further, when particle size was measured under different shaking intensities in the horizontal setup, no significant change in nanoparticle size was observed regardless of shaking strength or time after preparation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In the reconstitution of Abraxane\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , the optimal shaking condition identified in this study was demonstrated to not only preserve nanoparticle integrity but also reduce the time and effort required for healthcare professionals.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251403954","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:07:26Z","timestamp":1767985646000},"page":"560-568","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Improved preparation of Abraxane\n                    <sup>\u00ae<\/sup>\n                    I.V. Infusion (paclitaxel nanoparticles)"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0087-7212","authenticated-orcid":false,"given":"Tomoaki","family":"Toyama","sequence":"first","affiliation":[{"name":"Dokkyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-3568","authenticated-orcid":false,"given":"Hironori","family":"Betsunoh","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University Hospital"},{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7324-8908","authenticated-orcid":false,"given":"Takeshi","family":"Oshizaka","sequence":"additional","affiliation":[{"name":"Josai International University"},{"name":"Josai International University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Mimura","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5123-4714","authenticated-orcid":false,"given":"Takuya","family":"Sotome","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Josai International University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Josai International University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Mori","sequence":"additional","affiliation":[{"name":"Josai International University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sugibayashi","sequence":"additional","affiliation":[{"name":"Josai International University"},{"name":"Josai University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-5923","authenticated-orcid":false,"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University Hospital"},{"name":"Dokkyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Usui","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/277665a0"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00738a045"},{"key":"e_1_3_3_4_2","unstructured":"Holton RA. Antitumor agent. European Patent Application EP0400971A2 1990."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202219114"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00083a067"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/asia.200600156"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/chem.201404295"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg036"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2054"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.15.1169"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c24-00838"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00171-X"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/11634690-000000000-00000"},{"key":"e_1_3_3_15_2","volume-title":"Abraxane\u00ae for Intravenous Infusion 100 mg [package insert]","author":"Taiho Pharmaceutical Co., Ltd.","year":"2025","unstructured":"Taiho Pharmaceutical Co., Ltd. Abraxane\u00ae for Intravenous Infusion 100 mg [package insert]. Tokyo, Japan: Taiho Pharmaceutical Co., Ltd., 2025, Japanese."},{"key":"e_1_3_3_16_2","first-page":"1038","article-title":"Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel","volume":"8","author":"Ibrahim NK","year":"2002","unstructured":"Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8: 1038\u20131044.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_17_2","first-page":"1105","article-title":"Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol","volume":"53","author":"Huang S","year":"2018","unstructured":"Huang S, Wang Y, Chen Y, et al. Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol. Int J Oncol 2018; 53: 1105\u20131117.","journal-title":"Int J Oncol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30327-9"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.04.010"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2014.07.030"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.08.016"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biortech.2014.09.060"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251403954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251403954","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251403954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:32:02Z","timestamp":1777689122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251403954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/10781552251403954"],"URL":"https:\/\/doi.org\/10.1177\/10781552251403954","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}